Description of Insight Molecular Diagnostics Inc's Business Segments

iMDx is an early-stage diagnostics technology company engaged in the research, development, and commercialization of diagnostic tests. The company organizes its business based on products and services under a management approach overseen by the Chief Executive Officer and Chief Financial Officer. Its primary revenues are generated from Laboratory Services for life sciences customers, including biomarker discovery, assay design and development, clinical trial support, and biomarker tests, with additional revenue from Kitted Products. iMDx focuses on developing diagnostic tests related to organ transplant and oncology. The company's single reportable segment comprises Laboratory Services, Laboratory Developed Test Services, and Kitted Products. The Chief Operating Decision Maker evaluates segment performance and allocates resources using adjusted earnings or loss before interest, income taxes, depreciation, and amortization. Segment loss includes revenues, cost of revenues, research and development, and other operating expenses directly attributable to the segment, excluding depreciation, amortization, stock-based compensation, changes in fair value of contingent consideration, and impairments. Segment assets correspond to total assets reported in the consolidated balance sheets, and expenditures for long-lived assets are reflected in cash flows from investing activities.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Insight Molecular Diagnostics Inc Revenues by Segments


UNITED STATES		2.51 %	of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
UNITED STATES	0.01	2.51 %
Total	0.24	100 %

Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
UNITED STATES	-98.79 %	-81.25 %
Total	-53.86 %	646.88 %

Q2 three months ended (Jun 30 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Total	-11.26	-

Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Total	-	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.